LOPERAMIDE VIATRIS CONSEIL 2 mg, lyophilizate oral 12 oral lyophilisates
Active ingredients: Loperamide hydrochloride, Loperamide
Commercialized according to BDPM
Lyophilizate12 oral lyophilisatesorale
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- LOPERAMIDE VIATRIS CONSEIL 2 mg, lyophilisat oral
- Pharmaceutical form
- lyophilisat
- Route of administration
- orale
- Presentation description
- plaquettes (PVC/polyamide/aluminium/PVC) avec opercule détachable en (Papier/PET/Aluminium) de 12 lyophilisats oraux
- Marketing authorisation holder
- VIATRIS SANTE
- Reimbursement according to BDPM
- —
- Approval for use in healthcare institutions
- non
- Commercialization declaration date
- 29 Jul 2022
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
64433231CIP73024192CIP133400930241929Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| CHLORHYDRATE DE LOPÉRAMIDElyophilisat | 2 mg · un lyophilisat | SA |
| LOPÉRAMIDE BASElyophilisat | 1,85 mg · un lyophilisat | FT |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.
The current BDPM data does not list similar medicines for this product.